Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.22
CRDC's Cash to Debt is ranked higher than
70% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.78 vs. CRDC: 2.22 )
CRDC' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 2.22

Equity to Asset 0.36
CRDC's Equity to Asset is ranked higher than
51% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. CRDC: 0.36 )
CRDC' s 10-Year Equity to Asset Range
Min: -5.64   Max: 0.86
Current: 0.36

-5.64
0.86
F-Score: 3
Z-Score: -20.42
M-Score: -4.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -447.56
CRDC's Operating margin (%) is ranked lower than
55% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.96 vs. CRDC: -447.56 )
CRDC' s 10-Year Operating margin (%) Range
Min: -1065.07   Max: -26.6
Current: -447.56

-1065.07
-26.6
Net-margin (%) -461.19
CRDC's Net-margin (%) is ranked lower than
55% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. CRDC: -461.19 )
CRDC' s 10-Year Net-margin (%) Range
Min: -1281.1   Max: -26.56
Current: -461.19

-1281.1
-26.56
ROE (%) -147.05
CRDC's ROE (%) is ranked lower than
54% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. CRDC: -147.05 )
CRDC' s 10-Year ROE (%) Range
Min: -274.75   Max: -39.69
Current: -147.05

-274.75
-39.69
ROA (%) -90.86
CRDC's ROA (%) is ranked lower than
55% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. CRDC: -90.86 )
CRDC' s 10-Year ROA (%) Range
Min: -166.39   Max: -30.66
Current: -90.86

-166.39
-30.66
ROC (Joel Greenblatt) (%) -495.41
CRDC's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. CRDC: -495.41 )
CRDC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1063.59   Max: -493.28
Current: -495.41

-1063.59
-493.28
Revenue Growth (%) -20.60
CRDC's Revenue Growth (%) is ranked higher than
52% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. CRDC: -20.60 )
CRDC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 13.6
Current: -20.6

0
13.6
EBITDA Growth (%) -7.80
CRDC's EBITDA Growth (%) is ranked higher than
61% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. CRDC: -7.80 )
CRDC' s 10-Year EBITDA Growth (%) Range
Min: -54.9   Max: -1.1
Current: -7.8

-54.9
-1.1
EPS Growth (%) -7.20
CRDC's EPS Growth (%) is ranked higher than
64% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.80 vs. CRDC: -7.20 )
CRDC' s 10-Year EPS Growth (%) Range
Min: -51.5   Max: 1.3
Current: -7.2

-51.5
1.3
» CRDC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRDC Guru Trades in Q1 2013

PRIMECAP Management 2,599,300 sh (+120.41%)
Jim Simons 138,100 sh (-9.26%)
» More
Q2 2013

CRDC Guru Trades in Q2 2013

PRIMECAP Management 2,599,600 sh (+0.01%)
Jim Simons 98,500 sh (-28.67%)
» More
Q3 2013

CRDC Guru Trades in Q3 2013

PRIMECAP Management 2,599,600 sh (unchged)
Jim Simons 81,189 sh (-17.57%)
» More
Q4 2013

CRDC Guru Trades in Q4 2013

PRIMECAP Management 2,599,600 sh (unchged)
Jim Simons 49,500 sh (-39.03%)
» More
» Details

Insider Trades

Latest Guru Trades with CRDC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-03-31 Add 120.41%$1.1 - $1.68 $ 0.9-34%2599300
PRIMECAP Management 2012-06-30 Add 50.94%$1.69 - $2.2 $ 0.9-54%1031600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.25
CRDC's P/B is ranked lower than
67% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. CRDC: 11.25 )
CRDC' s 10-Year P/B Range
Min: 1.26   Max: 15.73
Current: 11.25

1.26
15.73
P/S 11.25
CRDC's P/S is ranked lower than
76% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. CRDC: 11.25 )
CRDC' s 10-Year P/S Range
Min: 1.54   Max: 35.68
Current: 11.25

1.54
35.68

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 90.00
CRDC's Price/Net Current Asset Value is ranked lower than
76% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. CRDC: 90.00 )
CRDC' s 10-Year Price/Net Current Asset Value Range
Min: 2.22   Max: 110
Current: 90

2.22
110
Price/Tangible Book 11.25
CRDC's Price/Tangible Book is ranked lower than
70% of the 227 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. CRDC: 11.25 )
CRDC' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 14.33
Current: 11.25

1.68
14.33
Price/Median PS Value 0.82
CRDC's Price/Median PS Value is ranked higher than
84% of the 264 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. CRDC: 0.82 )
CRDC' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.94
Current: 0.82

0.16
1.94
Forward Rate of Return (Yacktman) -60.93
CRDC's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.47 vs. CRDC: -60.93 )
CRDC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -36.6   Max: -23.9
Current: -60.93

-36.6
-23.9

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:C5V.Germany
Cardica, Inc. was incorporated in Delaware in October 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Its business is focused on the design, manufacture and marketing of proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. It has re-focused its business on the development of an endoscopic microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons. The first product that it is developing in its planned microcutter product line is the Microcutter XPRESS 30, the first true multi-fire endolinear microcutter device based on its proprietary 'staple-on-a-strip' technology, which would expand its commercial opportunity into additional surgical markets. In addition, it is developing the Microcutter XPRESS 45, a planned multi-fire endolinear microcutter device with a 45 millimeter staple line, the Microcutter XCHANGE 30, a planned cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line, the Microcutter FLEXCHANGE 30, a planned cartridge based microcutter device with a flexible shaft to facilitate endoscopic procedures requiring cutting and stapling, and the Microcutter XPRESS 60, a planned cutting and stapling device designed for the bariatric and thoracic surgery markets. The Company's C-Port Distal Anastomosis Systems, or C-Port systems, are sold in the United States and Europe. The C-Port systems are used to perform a distal anastomosis, which is the connection between a bypass graft vessel and the target coronary artery. It intends to launch a full range of surgical stapling devices that cover the needs of thoracic, bariatric, colorectal and general surgeons. It designs, manufactures and markets proprietary automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump CABG procedures. It currently markets four proprietary products to perform anastomoses, the C-Port xA system, the C-Port Flex A system, the C-Port X-CHANGE system and the PAS-Port system. The FDA and other regulatory bodies extensively regulate the research, development, manufacture, labeling, distribution and marketing of its products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide